BioNanomatrix is developing pioneering nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome.
Until now, whole genome analysis has been prohibitively slow, complicated and expensive. BioNanomatrix is applying its patented nanoscale technology to develop a unique platform that can rapidly and cost effectively analyze individual long strands of DNA in sequence and in a massively parallel format. The BioNanomatrix technology delivers comprehensive analyses of DNA and other genome-related peptides and proteins with single-molecule and single-cell sensitivity, while avoiding the fragmentation and complex data re-assembly required by other approaches. The affordability, speed and simplicity of the technology are expected to make the routine use of genetic information feasible in broad-ranging applications including genetic diagnostics, personalized medicine and biomedical research
BioNanomatrix’s development programs are partly supported by grants from the National Institutes of Health and an $8.8 million government award to jointly develop a platform capable of sequencing the entire human genome at a cost of just $100. The company is also collaborating with commercialization partners for nearer-term applications.
Founded in 2003 with technology exclusively licensed from Princeton University, BioNanomatrix is headquartered in Philadelphia, Pennsylvania.